Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eargo, Inc.EAR · Entity 94112 | Director | November 22, 2022 | November 25, 2022 |
| Immunovant, Inc.IMVT · Entity 3632 | Director | April 07, 2026 | April 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eargo, Inc.
Report date November 22, 2022 · Filed November 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,072 |
Reported balance
After 2022-11-22 transaction · row 1
1 source rowRow 1 · 2022-11-22 · Other · Acquired 71,363 · Balance 107,072 F1: Represents shares of the Issuer's Common Stock acquired by the Reporting Person following the exercise of his basic subscription rights in connection with the Issuer's rights offering to holders of Common Stock, as described in the issuer's prospectus dated October 27, 2022 (the "Rights Offering"). Each holder of Common Stock of record as of October 24, 2022 received one right for each share of Common Stock, and each right entitled the holder of Common Stock to purchase 9.5151 shares of Common Stock at the subscription price of $0.50 per whole share. |
| Subscription Rights (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 | Direct | 0 |
Reported balance
After 2022-11-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-23 · Other · Disposed 7,500 · Balance 0 F2: Represents exercise price per whole share of Common Stock. F3: The Rights Offering expired on November 17, 2022, and final determination of the pro rata allocation for each exercising holder was determined on November 22, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's Common Stock acquired by the Reporting Person following the exercise of his basic subscription rights in connection with the Issuer's rights offering to holders of Common Stock, as described in the issuer's prospectus dated October 27, 2022 (the "Rights Offering"). Each holder of Common Stock of record as of October 24, 2022 received one right for each share of Common Stock, and each right entitled the holder of Common Stock to purchase 9.5151 shares of Common Stock at the subscription price of $0.50 per whole share.
F2: Represents exercise price per whole share of Common Stock.
F3: The Rights Offering expired on November 17, 2022, and final determination of the pro rata allocation for each exercising holder was determined on November 22, 2022.
Immunovant, Inc.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,653 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 13,880 · Balance 134,653 F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2036-04-07 | Direct | 7,061 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Grant · Acquired 7,061 · Balance 7,061 F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
F2: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2026 Filed Apr 9, 2026 20:26 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 7,061 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001764013-26-000048 · wk-form4_1775766410.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,061 Underlying: Common Stock · 7,061 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:26 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 13,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-26-000048 · wk-form4_1775766410.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,653 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 23:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,909 | $23.96 | $45,739.64 |
DisclosureSEC source: 0001764013-25-000159 · wk-form4_1764803660.xml · nonDerivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,773 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 - $24.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 23:14 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 13,091 | $23.14 | $302,925.74 |
DisclosureSEC source: 0001764013-25-000159 · wk-form4_1764803660.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,682 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.75 - $23.73 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:43 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 7,600 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:43 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 16,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000045 · wk-form4_1743712974.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,773 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 5,425 | $28.54 | $154,829.50 |
DisclosureSEC source: 0001764013-24-000199 · wk-form4_1733347209.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,585 F1 · shares: The sale of shares of common stock reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2023 in order to satisfy applicable tax obligations arising in connection with the vesting and deferred settlement of a prior award of restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.05 - $28.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:50 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 4,690 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000065 · wk-form4_1712263802.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 4,690 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:50 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 11,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000065 · wk-form4_1712263802.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,010 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 2, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:35 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 16,260 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001764013-23-000046 · wf-form4_168150451547406.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Underlying: Common Stock · 16,260 shares Expires 2033-04-12 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on April 12, 2024, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:35 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 12,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000046 · wf-form4_168150451547406.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,755 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on April 12, 2024, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 18:05 UTC | Eargo, Inc. EAR · Entity 94112 | OtherSubscription Rights (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000899243-22-037001 · doc4.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,363 shares Expires not disclosed F2 · derivative.exercise_price: Represents exercise price per whole share of Common Stock. F3 · derivative.expiration_date: The Rights Offering expired on November 17, 2022, and final determination of the pro rata allocation for each exercising holder was determined on November 22, 2022. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 18:05 UTC | Eargo, Inc. EAR · Entity 94112 | OtherCommon Stock | 71,363 | $0.50 | $35,681.50 |
DisclosureSEC source: 0000899243-22-037001 · doc4.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,072 F1 · shares: Represents shares of the Issuer's Common Stock acquired by the Reporting Person following the exercise of his basic subscription rights in connection with the Issuer's rights offering to holders of Common Stock, as described in the issuer's prospectus dated October 27, 2022 (the "Rights Offering"). Each holder of Common Stock of record as of October 24, 2022 received one right for each share of Common Stock, and each right entitled the holder of Common Stock to purchase 9.5151 shares of Common Stock at the subscription price of $0.50 per whole share. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 20:05 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Options (Right to Buy) · Derivative | 74,074 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000899243-22-033643 · doc4.xml · derivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,074 Underlying: Common Stock · 74,074 shares Expires 2032-10-11 F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 23:36 UTC | Eargo, Inc. EAR · Entity 94112 | GrantStock Options (Right to Buy) · Derivative | 74,805 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-22-029777 · doc4.xml · derivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,805 Underlying: Common Stock · 74,805 shares Expires 2032-08-22 F1 · derivative.exercise_date: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of November 9, 2021, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:41 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 31,668 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001764013-22-000091 · wf-form4_166094167115623.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,668 Underlying: Common Stock · 31,668 shares Expires 2032-08-17 F3 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on August 17, 2023, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:41 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 21,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000091 · wf-form4_166094167115623.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,232 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety one year after the date of grant on August 17, 2023, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:00 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 71,492 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001764013-22-000017 · wf-form4_164202480829515.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,973 Underlying: Common Stock · 71,492 shares Expires 2032-01-10 F3 · derivative.exercise_date: Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 22:00 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 21,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000017 · wf-form4_164202480829515.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,173 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 13:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | PurchaseCommon Stock | 18,247 | $8.24 | $150,355.28 |
DisclosureSEC source: 0001764013-21-000092 · wf-form4_163032892005129.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,447 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.22 - $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 21:14 UTC | Eargo, Inc. EAR · Entity 94112 | SaleCommon Stock | 1,500 | $55.00 | $82,500.00 |
DisclosureSEC source: 0000899243-21-017193 · doc4.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,709 F1 · kind: The transaction was made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:52 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 23,300 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000042 · wf-form4_161650393243276.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,300 Underlying: Common Stock · 23,300 shares Expires 2031-03-19 F2 · derivative.exercise_date: The shares underlying the options vest one year after the date of grant on March 19, 2022, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:52 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000042 · wf-form4_161650393243276.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,200 F1 · shares: Represents the number of shares underlying restricted stock unit awards ("RSUs") granted to the Reporting Person pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in their entirety one year after the date of grant on March 19, 2022, subject to the Reporting Person's continued service to the Issuer as of such date; provided that the Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 23:29 UTC | Eargo, Inc. EAR · Entity 94112 | ConversionSeries C Preferred Stock · Derivative | 33,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029075 · doc4.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,209 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 23:29 UTC | Eargo, Inc. EAR · Entity 94112 | ConversionCommon Stock | 37,209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029075 · doc4.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock automatically converted into shares of Common Stock on a 1:1.118772093 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001209191-20-029936 · doc4.xml · derivative · entry 2 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2030-05-14 F2 · derivative.exercise_date: The shares underlying the option vest in eight equal quarterly installments measured from May 15, 2020, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 24,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029936 · doc4.xml · nonDerivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,700 F1 · shares: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. F1 · price: Represents the number of shares underlying restricted stock units awards ("RSUs") pursuant to a non-employee director grant. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in two equal annual installments on May 15, 2021 and May 15, 2022, subject to the Reporting Person's continued service to the Issuer as of each such date; provided that each director may elect to defer settlement of the RSUs upon vesting, subject to Rule 409A regulation. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:53 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 77,181 | Not disclosed Strike: $8.43 | Not disclosed |
DisclosureSEC source: 0001209191-19-061590 · doc4.xml · derivative · entry 1 Hughes Douglas J. · CIK 0001710863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,181 Underlying: Common Stock · 77,181 shares Expires 2029-11-19 F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 157,812 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1 · derivative.exercise_date: This stock option vests over a period of three years, with 1/3 of the shares underlying the option vesting on each of the first, second and third anniversaries of the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.